Novavax reports success for NVX-CoV2373 in pediatric group of phase 3 trial

Novavax said that its Covid-19 vaccine NVX-CoV2373 achieved its primary effectiveness endpoint in the pediatric expansion of its phase 3 PREVENT-19 trial. According to the ... Read More